Scholarlink

<p>A new series of amide derivatives of oxazol-2-yl)pyrazin-2-yl)-5-(pyridin-4-yl)-1,3,4-oxadiazole derivatives were designed, synthesized and evaluated in-vitro anticancer activities against breast cancer (MCF-7), lung cancer (A549), colon cancer (Colo-205) and ovarian cancer (A2780) by using of MTT assay, and the etoposide used as reference drug. The IC<sub>50</sub> values ranges of compound from 0.23 ± 0.045 µM to 7.38 ± 5.62 µM, where etoposide showed values ranges from 0.17 ± 0.034 µM to 3.34 ± 0.152 µM. Most of the tested derivatives were showed good to moderate activities than etoposide. This study investigates the multitarget anticancer potential of compounds <b>21a–21d</b> through molecular docking and ADME–Tox analysis. The compounds demonstrated strong binding affinities and critical interactions with EGFR and VEGFR2, indicating their potential to modulate key cancer-associated pathways, including proliferation and angiogenesis. ADME–Tox predictions revealed good solubility but identified limitations such as low intestinal absorption, P-gp–mediated efflux, and inhibition of multiple CYP450 isoforms, highlighting the need for further structural optimization. Overall, these findings provide mechanistic insights supporting the potential of this scaffold in multitarget-oriented anticancer drug discovery.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Synthesis, in-vitro anticancer evaluation and in-silico molecular docking studies of oxazol-2-yl)pyrazin-2-yl)-5-(pyridin-4-yl)-1,3,4-oxadiazole derivatives

  • 期刊论文

  • 发表日期：

    2026年4月28日

查看全文
  • Garikipati Karuna Deepthi,
  • Reddymasu Sreenivasulu,
  • Mandava Bhuvan Tej,
  • Swathi Thumula,
  • Ravi Kumar Kapavarapu,
  • Mandava Venkata Basaveswara Rao

摘要

A new series of amide derivatives of oxazol-2-yl)pyrazin-2-yl)-5-(pyridin-4-yl)-1,3,4-oxadiazole derivatives were designed, synthesized and evaluated in-vitro anticancer activities against breast cancer (MCF-7), lung cancer (A549), colon cancer (Colo-205) and ovarian cancer (A2780) by using of MTT assay, and the etoposide used as reference drug. The IC50 values ranges of compound from 0.23 ± 0.045 µM to 7.38 ± 5.62 µM, where etoposide showed values ranges from 0.17 ± 0.034 µM to 3.34 ± 0.152 µM. Most of the tested derivatives were showed good to moderate activities than etoposide. This study investigates the multitarget anticancer potential of compounds 21a–21d through molecular docking and ADME–Tox analysis. The compounds demonstrated strong binding affinities and critical interactions with EGFR and VEGFR2, indicating their potential to modulate key cancer-associated pathways, including proliferation and angiogenesis. ADME–Tox predictions revealed good solubility but identified limitations such as low intestinal absorption, P-gp–mediated efflux, and inhibition of multiple CYP450 isoforms, highlighting the need for further structural optimization. Overall, these findings provide mechanistic insights supporting the potential of this scaffold in multitarget-oriented anticancer drug discovery.

Graphical abstract